USA flag logo/image

An Official Website of the United States Government

Tissue Factor Antagonists for ALI/ARDS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75804
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
HL082397
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
X
2810 N COMMERCE PKY MIRAMAR, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2006
Title: Tissue Factor Antagonists for ALI/ARDS
Agency: HHS
Contract: 4R44HL082397-02
Award Amount: $2,079,846.00
 

Abstract:

DESCRIPTION (provided by applicant): The objective of this project is to develop an anti-tissue factor antibody, Sunol-cH36, as a treatment for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The association between coagulation and inflammation has been well established and a central role in the coagulopathy of ALI/ARDS has been attributed to tissue factor (TF). TF binding to Factor VIIa (FVIIa) activates FX to FXa, forming a transient ternary complex, TF-FVIIa-FXa, which is involved in inflammatory signaling by generating downstream products of activated coagulation and by signal initiation by the TF complex itself. The latter involves signal transduction through the cytoplasmic tail of TF or sequential presentation of FVIIa and FXa to protease activated receptors (PARs) on the cell surface. In vitro, TF-dependent FVIIa and FXa action on PARs have independent, pro-inflammatory effects that include upregulation of cytokine gene expression. These discrete signaling events (signal transduction by the TF intracellular domain and TF activation of PARs) represent unique opportunities for intervention. We hypothesized that blockade of FX binding to established TF-FVIIa complex by Sunol-cH36 would attenuate coagulation-dependent inflammatory responses in ALI and ARDS. In addition, TF blockade by Sunol-cH36 may also attenuate the coagulation-independent intracellular signaling. The safety of Sunol-cH36 has been previously established in numerous preclinical studies and in a phase 1 clinical trial for coronary artery disease. The specific aims of the current proposal will evaluate the pharmacokinetics and toxicity of Sunol-cH36 when multiple doses are administered to cynomolgus monkeys. The results from the current proposal will complete pre-clinical pharmacokinetic and toxicology studies to support a regulatory approval from the FDA to advance the molecule into clinical development using a multiple dose regimen.

Principal Investigator:

Jack O. Egan
9544438600
JACKEGAN@ALTOBIOSCIENCE.COM

Business Contact:

Hing Wong
9544438600
hingwong@altorbioscience.com
Small Business Information at Submission:

ALTOR BIOSCIENCE CORPORATION
ALTOR BIOSCIENCE CORPORATION 2810 N COMMERCE PKY MIRAMAR, FL -

EIN/Tax ID: 050523659
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No